To compare the effect of EGFR monotherapies to the predicted individualized targeted therapies on immune response, we treated HNSCC cell lines with either monotherapies, or combined therapies, and examined a change in the secreted levels of interferon gamma (IFN-γ) in response to different treatments (Figure 5A, left panel). This evidence concerns the gene IFNG and head and neck squamous cell carcinoma.